Fed’s Powell opens door to potential rate cuts at Jackson Hole
Investing.com - Benchmark lowered its price target on Intensity Therapeutics , Inc. (NASDAQ:INTS) to $1.50 from $4.00 on Wednesday, while maintaining a Speculative Buy rating on the stock. The company, currently trading at $0.29 with a market cap of $13.9 million, has seen its shares decline over 93% in the past year according to InvestingPro data.
The research firm cited recent share dilution as the primary reason for the reduced target, despite maintaining its positive outlook on the company’s prospects.
Intensity Therapeutics reported second-quarter 2025 financial results showing net losses of $2.5 million or ($0.13) per share, an improvement from losses of $5.0 million or ($0.36) per share in the same period last year.
The clinical-stage biotechnology company highlighted enrollment progress and early promising data for its Invincible-3 and Invincible-4 late-stage trials during the quarter.
Intensity also completed successful equity raises that extended its cash runway through the second half of 2026, according to Benchmark’s research note.
In other recent news, Intensity Therapeutics reported promising results from its Phase 2 INVINCIBLE-4 study, where the experimental cancer drug INT230-6 demonstrated high levels of tumor necrosis in early-stage patients. These findings come as the company progresses with its clinical trials aimed at treating triple-negative breast cancer. Intensity Therapeutics also announced a public offering of common stock, with plans to use the proceeds to support ongoing studies and general corporate needs. The offering is managed by ThinkEquity.
Additionally, Intensity Therapeutics regained compliance with Nasdaq’s minimum stockholders’ equity requirement, meeting the $2.5 million threshold. In governance matters, shareholders elected Mark A. Goldberg as a Class II director at the annual meeting, where they also approved the company’s auditor. On the financial front, Brookline Capital Markets upgraded Intensity Therapeutics’ stock rating from Hold to Buy, citing positive clinical developments and an improved financial position. This upgrade sets a price target of $3.00 for the company’s shares.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.